News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nanosyn Inc. Announces Opening of Its First Branch on the East Coast


10/21/2008 8:49:51 AM

MENLO PARK, Calif., Oct. 21 /PRNewswire/ -- Nanosyn announced today that it has acquired assets left from the ceased operations of Amphora Discovery Corporation and opened its first branch on the East Coast in Research Triangle Park (RTP), North Carolina. This move is part of Nanosyn's strategy to become a worldwide leader in drug discovery services and reflects the company's evolution from a small regional operation to a larger business on a global scale.

The acquired assets include an industrialized system encompassing high precision microfluidic-based assays, hardware, screening protocols, etc. This new site is currently fully operational and has retained the highly qualified and best in class staff of former Amphora Discovery for screening operations.

"It is a natural expansion for us," said Nikolai Sepetov, Ph.D, President and CEO of Nanosyn. "After 10 years of growth as a pure chemistry CRO, we are adding biology services to our clients as many of them are looking for more integrated solutions. Since we can provide both new chemistry and biology in house, we can significantly speed up the drug discovery process for our clients."

Nanosyn is also announcing that the Intellectual Property of former Amphora Discovery including all patents, early leads, and advanced lead programs are available for licensing, sale or joint development to interested parties.

For more information, please contact Olga Issakova, Ph.D., Executive Vice President; Phone: (650) 853-7034 or oissakova@nanosyn.com.

About Nanosyn

Nanosyn is a Contract Research Organization providing integrated drug discovery services, medicinal chemistry, made-to-order focused compound libraries, hit-to-lead optimization, screening and profiling services, process chemistry, and other innovative solutions to meet our partners drug discovery needs. Nanosyn's "Discovery on Demand" capabilities enable customers to apply the power of new screening technologies without making frustrating trade-offs between budgets, schedules, and research opportunities. Founded in 1998, Nanosyn is privately held and self-funding. The company is headquartered in Menlo Park, California with subsidiary sites in San Diego, California and Research Triangle Park, North Carolina. For more information, visit the company's web site at http://www.nanosyn.com.

CONTACT: Olga Issakova, Ph.D., Executive Vice President of Nanosyn,
+1-650-853-7034, oissakova@nanosyn.com

Web site: http://www.nanosyn.com/


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES